Core Viewpoint - Kangtuo Medical experienced a decline of 5.62% on September 11, with a stock price of 36.43 yuan per share and a total market capitalization of 2.96 billion yuan [1]. Company Overview - Xi'an Kangtuo Medical Technology Co., Ltd. was established on March 14, 2005, and went public on May 18, 2021. The company specializes in the research, production, and sales of three categories of implantable medical devices [1]. - The revenue composition of the company includes: 63.86% from PEEK material neurosurgical products, 22.54% from titanium material neurosurgical products, 10.97% from other products, and 2.62% from supplementary products [1]. Fund Holdings - Dongxing Fund has a significant holding in Kangtuo Medical, with the Dongxing Pharmaceutical Biotechnology Quantitative Selection Mixed A Fund (020830) holding 6,653 shares, representing 3.51% of the fund's net value, making it the sixth-largest holding [2]. - The fund has reported a floating loss of approximately 14,400 yuan as of the latest data [2]. Fund Manager Information - The fund manager of Dongxing Pharmaceutical Biotechnology Quantitative Selection Mixed A Fund is Li Bingwei, who has been in the position for 9 years and 93 days. The total asset size of the fund is 352 million yuan [3]. - During Li Bingwei's tenure, the best fund return was 61.7%, while the worst return was -11.19% [3].

Core Viewpoint - The company is preparing for its second extraordinary general meeting of shareholders in 2025, focusing on maintaining order and protecting shareholder rights during the meeting [2][3]. Meeting Guidelines - The meeting will only allow attendance from shareholders, company directors, senior management, and invited personnel, with strict entry regulations for others [2]. - Shareholders must register 30 minutes before the meeting and present necessary documentation to participate [3]. - The meeting will follow a predetermined agenda for discussing and voting on proposals [3][4]. Voting Procedures - Shareholders will have the right to speak, inquire, and vote during the meeting, but must adhere to time limits and order [4][5]. - Voting will be conducted through both on-site and online methods, with results announced post-meeting [6]. Financial Proposals - The company plans to distribute a cash dividend of 2 yuan per 10 shares, totaling approximately 16.25 million yuan, based on its 2025 half-year report [6][7]. - A proposal to provide financial assistance of up to 2 million USD to its associate company, BRANCHPOINT, is also on the agenda, aimed at supporting product development and registration [7][9]. Financial Assistance Details - The financial assistance will be at an interest rate of 5% per annum and is intended to be used for operational funding [9][10]. - The company has a pending investment obligation of 2 million USD to BRANCHPOINT, which can be offset against the financial assistance provided [10].

证券代码：688314 证券简称：康拓医疗 西安康拓医疗技术股份有限公司 2025 年第二次临时股东会会议资料 2025 年 9 月 1 2025 年第二次临时股东会会议须知 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证大 会的顺利进行，根据《中华人民共和国公司法》（以下简称"《公司法》"）《中 华人民共和国证券法》（以下简称"《证券法》"）《上市公司股东会规则》及 《西安康拓医疗技术股份有限公司章程》（以下简称"《公司章程》"）《西安康 拓医疗技术股份有限公司股东会议事规则》等相关规定，特制定 2025 年第二次 临时股东会会议须知： 一、为保证本次大会的严肃性和正常秩序，切实维护与会股东（或股东代理 人）的合法权益，除出席会议的股东（或股东代理人）、公司董事、高级管理人 员、见证律师及董事会邀请的人员外，公司有权依法拒绝其他无关人员进入会场。 二、出席会议的股东及股东代理人须在会议召开前半小时到会议现场办理签 到手续，并按规定出示证券账户卡、身份证明文件或营业执照复印件（加盖公章）、 授权委托书等，上述登记材料均需提供复印件一份，个人登记材料复印件须个人 签字，法定代表人证明文件复印件 ...

Company Overview - Kangtuo Medical, established on March 14, 2005, is located in Xi'an, Shaanxi Province, and was listed on May 18, 2021. The company specializes in the research, production, and sales of three types of implantable medical devices [1] - The company's main business revenue composition includes: PEEK material neurosurgical products (63.86%), titanium material neurosurgical products (22.54%), other products (10.97%), and supplementary products (2.62%) [1] Stock Performance - On September 3, Kangtuo Medical's stock rose by 5.04%, reaching a price of 38.16 CNY per share, with a trading volume of 71.24 million CNY and a turnover rate of 2.36%. The total market capitalization is 3.1 billion CNY [1] Fund Holdings - Dongxing Fund has a significant holding in Kangtuo Medical, with its Dongxing Pharmaceutical Biotechnology Quantitative Selection Mixed A Fund (020830) holding 6,653 shares, accounting for 3.51% of the fund's net value, making it the sixth-largest holding [2] - The fund has achieved a year-to-date return of 36.69%, ranking 1474 out of 8180 in its category, and a cumulative return of 29.01% since its inception [2] Fund Manager Profile - The fund manager of Dongxing Pharmaceutical Biotechnology Quantitative Selection Mixed A Fund is Li Bingwei, who has been in the position for 9 years and 85 days. The total asset size of the fund is 352 million CNY, with the best return during his tenure being 62.49% and the worst being -11.19% [3]

Core Viewpoint - The company plans to distribute a cash dividend of 2 RMB per 10 shares (including tax) to all shareholders, subject to approval at the upcoming shareholder meeting [1][2]. Summary by Sections Profit Distribution Plan - As of June 30, 2025, the company's undistributed profits amount to RMB 67.5 million, and the proposed cash dividend represents 29.54% of the net profit attributable to shareholders for the first half of 2025 [1]. Decision-Making Process - The company's board of directors approved the profit distribution proposal on August 27, 2025, with a unanimous vote of 9 in favor. This proposal will be submitted for approval at the 2025 second extraordinary general meeting of shareholders [2]. Adjustments for Changes in Share Capital - If there are changes in the total share capital due to convertible bonds, share buybacks, or other corporate actions before the record date, the total distribution amount will remain unchanged, but the per-share distribution will be adjusted accordingly [2].

证券代码：688314 证券简称：康拓医疗 公告编号：2025-036 西安康拓医疗技术股份有限公司 关于召开2025年第二次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 股东会召开日期：2025年9月16日 ? 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 一、 召开会议的基本情况 （一） 股东会类型和届次 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相 结合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 9 月 16 日 14 点 00 分 召开地点：西安市高新区毕原一路西段 1451 号西安康拓医疗技术股份有限 公司三楼会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 9 月 16 日 至2025 年 9 月 16 日 A 股股东 非累积投票议案 本次提交股东会审议的议案已经公司第二届董事会第十八次会 ...

Core Viewpoint - Xi'an Kontour Medical Technology Co., Ltd. reported a revenue increase of 11.07% and a net profit increase of 12.72% for the first half of 2025, indicating strong growth in the medical device sector, particularly in neurosurgery and PEEK material products [1][14]. Company Overview and Financial Indicators - The company specializes in the research, production, and sales of Class III implantable medical devices, focusing on neurosurgery, thoracic surgery, and oral surgery [5][13]. - As of June 30, 2025, the company reported total assets of RMB 778.07 million, with a net asset value of RMB 680.69 million, reflecting a year-on-year increase of 4.13% and 7.10% respectively [3][14]. - The company achieved a total revenue of RMB 170.32 million and a total profit of RMB 65.36 million for the first half of 2025 [3][14]. Industry Context - The company operates within the specialized equipment manufacturing industry, specifically in the biomedical engineering sector, which is experiencing growth due to aging populations and increasing health demands [14]. - The implementation of centralized procurement policies is driving the clinical penetration of high-value medical consumables, benefiting companies like Kontour Medical [14][15]. Business Performance - The neurosurgery segment generated RMB 149.04 million in revenue, a 12.01% increase from the previous year, with PEEK material products contributing RMB 108.77 million, up 13.05% [14][15]. - The thoracic surgery segment reported revenue of RMB 1.17 million, with PEEK material products showing a 20.28% increase [15]. - The company has successfully expanded its market presence in the facial reconstruction sector, achieving RMB 5.06 million in revenue, a significant increase from the previous year [17]. Product Development and Innovation - The company holds 20 Class III implantable medical device registrations, with PEEK material products leading the domestic market [5][13]. - Ongoing research projects include the development of personalized PEEK facial implants and absorbable membranes, aimed at enhancing patient recovery and surgical outcomes [18]. - The company has initiated the production of PEEK bone plates in the U.S. and is expanding its product offerings in international markets [15][18]. Market Position - Kontour Medical maintains the largest market share in the domestic PEEK material cranial repair and fixation products, positioning itself as a leader in the neurosurgical implant sector [13][14]. - The company is leveraging its technological advantages to accelerate the replacement of traditional titanium materials with innovative PEEK solutions [14][15].

Core Viewpoint - Xi'an Kontuo Medical Technology Co., Ltd. reported a positive financial performance for the first half of 2025, with significant increases in revenue and net profit, alongside a planned cash dividend distribution to shareholders [1]. Financial Performance - Total assets as of the end of the reporting period amounted to ¥778,070,632.43, reflecting a 4.13% increase from the previous year [3]. - The net assets attributable to shareholders reached ¥680,693,200.44, up 7.10% compared to the previous year [3]. - Operating revenue for the period was ¥170,316,349.76, representing an 11.07% increase year-on-year [3]. - Total profit for the period was ¥65,359,324.72, which is a 10.27% increase from the previous year [3]. - Net profit attributable to shareholders was ¥54,998,635.19, marking a 12.72% increase compared to the same period last year [3]. - The basic earnings per share were ¥0.68, up 13.33% from ¥0.60 in the previous year [3]. Dividend Distribution - The company plans to distribute a cash dividend of ¥2 per 10 shares (including tax) to all shareholders, amounting to a total of ¥16,247,834.40 based on the total share capital of 81,239,172 shares [1].

Core Insights - 康拓医疗 reported a revenue of 170 million yuan for the first half of 2025, representing a year-on-year growth of 11.07% [1] - The company's net profit attributable to shareholders reached approximately 54.99 million yuan, marking a year-on-year increase of 12.72% [1] - The non-recurring net profit was about 50.39 million yuan, showing a significant year-on-year growth of 25.02% [1] - Basic earnings per share stood at 0.68 yuan [1] - The company proposed a cash dividend of 2 yuan (including tax) for every 10 shares to all shareholders [1]

Group 1 - Company announced the acquisition of approximately 55.50% equity in Xi'an Salamander Biotechnology Co., Ltd. and about 72.99% of the property interests in Xi'an Huicai Enterprise Management Consulting Partnership for a total price of approximately 84.98 million RMB [1] - Following the transaction, the company and its newly established wholly-owned subsidiary will directly hold 63.0001% of Salamander Biotechnology's equity and indirectly hold 27.0074% through Huicai, resulting in a total ownership of 90.0075% [1] - Salamander Biotechnology will become a subsidiary of the company and will be included in the consolidated financial statements [1] Group 2 - As of the report date, the company's market capitalization is 3 billion RMB [2] - The company's revenue composition for the year 2024 is projected to be 96.82% from medical device manufacturing and 3.18% from other businesses [1]